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ABSTRACT 
Introduction: The recent dramatic increase in the incidence of antimicrobial resistance 
has been recognized by organizations such as the United Nations and World Health 
Organization as well as the governments of the USA and several European countries. A 
relatively new weapon in the fight against severe infections caused by multi-drug 
resistant bacteria is antimicrobial peptides (AMPs). These include colistin, currently 
regarded as the last line of antimicrobial therapy against multi-drug resistant 
microorganisms. 
Areas covered: Here we provide an overview of current research on AMPs. The focus 
is AMPs currently being developed for the treatment of recalcitrant bacterial infections, 
the synergies of AMPs and antibiotics, and the activity of AMPs against biofilm. This 
review also includes a brief introduction to research in the use of AMPs in infections by 
Mycobacterium, fungi, and parasites. 
 Expert opinion: In research into new antimicrobials, AMPs are gaining increasing 
attention. While many are natural, produced by a wide variety of organisms, others are 
being newly designed and chemically synthesized in the laboratory to achieve novel 
antimicrobial agents. The same strategy to fight infections in nature is thus being 
effectively exploited to safeguard human and animal health. 
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1. INTRODUCTION 
Since the introduction of sulfonamides and the discovery of penicillin in 1928, the 
arsenal of drugs to treat infections has greatly expanded [1]. In fact, antibiotics have 
become the most commonly prescribed drugs and have greatly contributed to reducing 
mortality and morbidity due to infectious diseases. The “golden age of antibacterials” 
describes the period between the 1940s and 1960s, when the vast majority of antibiotics 
currently in use were discovered [2]. Unfortunately, the utility of these drugs has been 
seriously compromised by the subsequent emergence of resistant bacteria (Table 1). The 
mechanisms underlying resistance are both genetic and environmental. For example, 
bacteria can specifically limit or reduce the permeability of their cell envelope to a 
given antibiotic and thus become resistant. In the case of Pseudomonas aeruginosa, it 
can acquire resistance to imipenem by losing expression of the porin OprD, the 
transporter for this antibiotic, either by mutation or disruption of the respective gene [3].  
Alternatively, the bacterium may acquire the ability to degrade the antimicrobial, such 
as by. ß-lactamase production. This latter mechanism is of particular concern because 
the emergence of expanded spectrum ß-lactamases (ESBLs) has led to the emergence of 
new, non-responsive bacterial clones [4]. Resistance can also arise by the loss of 
chemical affinity between an antimicrobial and its target, as has commonly occurred in 
the case of streptococci; this mechanism was also the main cause of penicillin resistance 
in meningococci  [5,6]. The wide variety of efflux systems able to pump out 
antimicrobials from the bacterial cell is another worrisome mechanism of resistance 
because most of the pumps are highly unspecific [7]. It is also now appreciated that 
bacteria residing in biofilms have a much lower antimicrobial susceptibility than their 
planktonic or microcolonial counterparts [8]. 
The emergence of resistance is well illustrated by methicillin, discovered in 1959 and 
subsequently introduced to treat penicillin-resistant Staphylococcus aureus. However, 2 
years later, methicillin-resistant phenotypes strains were isolated, first in the United 
Kingdom and then in Japan, Australia, and elsewhere [9]. Similarly, the aminoglycoside 
streptomycin, which inhibits bacterial protein synthesis was introduced for the treatment 
of tuberculosis,, but the emergence of rRNA mutations conferring streptomycin-
resistance to Mycobacterium tuberculosis strains was soon reported [10].  
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The story has been the same for nearly every antibiotic, with the most recent example 
being lipopeptides, introduced at the beginning of this century. Strains resistant to at 
least one of them (daptomycin) are already known [11]. 
1.1. Antimicrobial resistance today 
The US Center for Disease Control and Prevention (CDC) reported in 2013 that in 2 
million people in the USA had suffered an infection caused by a resistant pathogen,and 
at least 23,000 of these individuals had died due to the infection. By about 2050, it is 
predicted that 10,000,000 deaths will be attributable to multi-resistant bacteria [12]. The 
Infectious Disease Society of America (IDSA) highlighted Enterococcus faecium, S. 
aureus, Klebsiella pneumoniae, Acinetobacter baumannii, P. aeruginosa, and 
Enterobacter (ESKAPE) as species capable of “escaping” the antibacterial action of 
antibiotics, including by the above-mentioned mechanisms. These species constitute a 
new paradigm in virulence, transmission, and antimicrobial resistance[13]. In 2014, the 
European Center for Disease Control published a report on antimicrobial resistance in 
Europe [14] that also focused on the ESKAPE pathogens. Increased levels of resistance, 
especially in southern European countries, was reported. 
The development and spread of antibiotic-resistant bacteria are, at least in part, the 
result of the use, misuse, and abuse of antimicrobial agents in human and veterinary 
medicine as well as the food industry. In fact more than half of the antibiotics prescribed 
are not needed or are incorrectly used. Particularly troublesome is the widespread use of 
antibiotics (in many cases illegally) in livestock to promote animal growth and in 
aquaculture to prevent the contamination of fish stocks. Antibiotics are also prescribed 
indiscriminately in both humans and household pets. They have also been used as 
additives in cleaning products[15]. 
1.2 Antimicrobial peptides.  
Antimicrobial peptides both natural and synthetic are one of the main options to 
overcome resistance.  Moreover, some peptides, particularly those that are similar to 
animal defense AMPs, have immunomodulatory activity [16].  
With the current dilemma of widespread resistance, including extremely resistant 
organisms, but a lack of availability of new antimicrobial agents, attempts are being 
made to “revive” older antimicrobials to treat serious infections. This is the case of 
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colistin (polymyxin E), a natural AMP whose use was abandoned due its toxicity [17]. 
However, colistin is the last option to treat infections caused by multi-drug resistant 
bacteria, including those caused by Pseudomonas aeruginosa and/or A. baumannii. 
Instead, new AMPs are in the drug discovery and development pipeline. 
  
2. MECHANISMS OF AMP ACTION AND RESISTANCE  
 
2.1. Mechanism of action  
Although membrane permeabilization is the main mechanism of action of AMPs against 
pathogens, additional mechanisms have been described, including membrane 
destabilization, inhibition of macromolecular synthesis, intracellular translocation of the 
peptide, and inhibition of DNA/RNA/protein synthesis [18]. The application of “omics” 
to the study of resistance mechanisms has enabled explorations of transcript profiles and 
the role of individual genes in response to AMP challenge. For example, the AMPs 
pleurocidin, magainin, D-LAK120-AP13, and buforin II induce changes in alanine, 
aspartate, and glutamate metabolism and in the expression of gltX, dapA, and metB, 
encoding, respectively, glutamyl-tRNA synthetase, dihydropicolinate synthase, and 
cystathionine gamma-synthase. Several genes are up-regulated in response to all four 
AMPs. Among them is yjjB, which encodes a 157-amino-acid, conserved, inner-
membrane protein predicted to have four trans-membrane helices but with unknown 
function. An integrated systems biology approach identified at least 1342 genes that are 
differentially expressed in response to the four AMPs. In E. coli, this accounts for 30% 
of the bacterial genome and provides evidence of the wide variety of genes whose 
expression is altered by AMPs but also of the large number of functions that can be 
manipulated by the bacteria to acquire AMP resistance [19].  
 
As polycationic peptides, AMPs interact electrostatically with negatively charged 
bacterial surface structures, including, lipoteichoic acids (gram-positive bacteria), and 
They then gain access to the cytoplasmic membrane and interact with lipid bilayers, 
forming transmembrane pores and resulting in a remarkable dose-dependent weakening 
of the membrane [20]. In addition, the peptide/lipid ratio determines the nature of AMP 
insertion into the membrane. At high peptide/lipid ratios, AMPs are perpendicularly 
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oriented and form transmembrane pores whereas at low ratios the AMPs insert parallel 
to the bacterial membrane. However, the presence of cholesterol in the lipid membrane 
may alter the interaction between peptides and phospholipids such that there is reduced 
disruption of the bilayer and therefore less leakage [21]. 
Several models have been proposed to specifically explain how AMPs induce 
membrane permeabilization:  
In the barrel-stave model,, after their membrane attachment, when a threshold 
concentration of the AMP is reached, the peptide monomers aggregate to form 
transmembrane pores within the hydrophobic membrane core. This model is consistent 
with the mechanism of action of the channel-forming peptide antibiotic alamethicin.  
In the toroidal pore model, the AMPs aggregate within the bilayer membranes such that 
the lipid monolayers to curve around the pore. The hydrophilic region of the AMP joins 
the bilayer membrane to form the outer part of the pore, while the hydrophobic part of 
forms its internal aspect. Consequently, the transmembrane pore is bordered by both the 
lipid head groups and the AMPs, allowing the water core to be lined. This model 
describes the mechanism of action of magainins (pexiganan, MSI-78) [22]  and of LL-
37  [23] .  
In the carpet model, AMPs are electrostatically attracted to the anionic phospholipids 
head groups and “carpet” the surface of the membrane. Thus, high concentrations of 
AMPs exert detergent-like effects, via the formation of micelles and pores that disrupt 
the bacterial membrane. However, at a critical concentration, these AMPs form toroidal 
transient pores  [18,20]. This model explains the mode of action of ovispirin, 
dermaseptin natural analogues, cecropins, trichogin, and some magainins [24].  
In the aggregate model, the electrostatic interactions between the phospholipid bilayer 
and the AMPs is followed by the formation of lipid-peptide complexes that induce the 
formation of non-specifically oriented pores with heterogeneous shapes and sizes. This 
allows the AMPs to transiently cross the membrane such that their bacterial-killing 
effects are related to their interactions with intracellular targets, such as polyanions, 
DNA or RNA [18,24]. This is the case for the AMPs buforin II, pleurocidin, and 
dermaseptin, which inhibit DNA or mRNA synthesis. 
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However, besides these various forms of membrane permeabilization and intracellular 
killing, other mechanisms of cell death have been proposed for AMPs, including the 
inhibition of extracellular biopolymer synthesis and intracellular functions [20,25]. For 
example, indolicin and PR-39 interfere with protein synthesis and pyrrhocoricin with 
correct protein folding. The lantibiotics nisin and mersacidin alter peptidoglycan 
synthesis whereas papiliocin induces the production of oxygen free radicals, which 
damages both DNA and ´the cell membrane. Finally, other AMPs can inhibit the 
activity of a few anionic enzymes.  As noted above, the wide variety of  mechanisms 
that lead to bacterial  killing are consistent with the large number of genes whose 
expression is altered by AMP challenge.  [18].  
2.2. Mechanisms of AMP resistance  
As with the development of antibiotic resistance, bacteria can become resistant to 
AMPs. The frequency  differs widely depending on the bacteria and the peptide [26]. 
Although the mechanisms of bacterial resistance to AMPs are not yet fully established, 
modification of the physical–chemical interaction between the AMP and the membrane 
to prevent permeabilization and the subsequent cellular osmotic imbalance is probably 
the first step in the development of bacterial resistance. The existence of mechanisms 
removing the peptides from their site of action has been reported as well as the 
emergence of new targets[27].   
Some microorganisms are able to reduce their net negative charge, either by introducing 
positively charged groups, such as basic amino acids (S. aureus) or by changing the 
electronegativity of the cytoplasmic membrane, by diminishing the content of anionic 
phospholipids (e.g. P. aeruginosa).  
Gram-positive pathogens such as Streptococcus agalactiae and Listeria monocytogenes 
neutralize the anionic charge of their wall by modifying teichoic acids with positively 
charged D-alanine residues. Other bacteria are surrounded by a capsule of 
polysaccharides that limits the interaction of AMPs with their targets. These capsule-
forming bacteria are more resistant to AMPs than mutants that lack a capsule [20,26].   
Among the strategies used by gram-negative bacteria to become resistant to AMPs is to 
decrease the anionic charge of lipid A (a main component of LPS) by acylation which 
reduces the fluidity of the outer membrane by increasing the hydrophobic interactions 
Page 6 of 40
URL: http://mc.manuscriptcentral.com/eobt  Email: David.Grech@informa.com
































































~ 7 ~ 
 
(e.g. in E. coli, Salmonella and Haemophilus influenza). Alternatively, they can modify 
phosphoryl choline, present on the membrane, [20,24,28], or the structure of their outer 
membrane proteins. The latter is the case in Yersinia enterocolitica, an ability conferred 
by a 70-kb plasmid [20]. A further mechanism in gram-negative bacteria involves their 
resistance-nodulation-cell division efflux pumps (RND transporters) and ATP-binding 
cassette transporters), both of which can pump out AMPs to avoid their action. This 
mechanism has been well-studied in E. coli, in which the yejABEF operon has been 
related to bacterial uptake of the AMP microcin C, and in Neisseria gonorrhea, in 
which the loss of the MtrCDE operon results in an enhanced  susceptibility to AMPs 
[20,28]. Down- egulation of host AMP expression is also a typical survival strategy of 
gram-negative pathogens, such as the down-regulation of LL-37 and hBD, produced by 
the host, 1 by exotoxins of Vibrio cholerae and enterotoxigenic E. coli [28].  
Finally, bacterial proteases usually have a broad spectrum of activity against peptides. 
The production of proteolytic enzymes by either gram-negative or gram-positive 
bacteria can result in the degradation of active AMP into inactive fragments and 
therefore AMP resistance. Thus, in gram-negative bacteria, mainly Enterobacteriaceae, 
the outer membrane  protein OmpT of E. coli is able to degrade AMPs [28]. In gram-
positive S. aureus, the same has been demonstrated for aureolysin [20].   
3. THERAPEUTIC APPLICATION OF ANTIMICROBIAL PEPTIDES 
AMPs hold several advantages as antimicrobials as they are less prone to generate 
microbial resistance than classical antibiotics. As discussed above, they act 
preferentially (but not exclusively) at the membrane level, may disrupt multiple 
biochemical processes in the pathogen, and may activate the immune system of the host. 
Nevertheless, there are still several pitfalls that need to be addressed regarding the 
development of their broader therapeutic application. These include the toxicity of 
AMPs, their pharmaceutical and pharmacological optimization (increased stability, 
reduced clearance rates), and the cost of their production. In fact, very few AMPs have 
reached the market. Of those that have, the majority are naturally-occurring cyclic 
peptides that usually contain non-coded amino acids (D-amino acids, for instance). 
 
4. THE PIPELINE OF ANTIMICROBIAL PEPTIDES 
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4.1 Cyclic AMPS  
Currently, there are roughly 20 AMPs in different development phases, from preclinical 
to clinical phase III trials (Table 2). A few are already clinically available, mainly but 
not only for topical applications [29].  
The first AMPs introduced for clinical use were cyclic compounds. Among those 
already available for several decades are polymyxins (polymyxin B and colistin, 
polymyxin E), gramicidin, tyrothricin (tyrocidin is the main component), bacitracin, and 
daptomycin (Fig. 1). Of these, the first AMP in clinical use in humans was tyrothricin. 
Discovered by René Dubos in 1939 as an active peptide produced by Bacillus brevis 
[1], it consists of a mixture of tyrocidine (~80%) and gramicidin (~20%). Tyrocidine 
itself is a complex mixture of cyclic peptides (tyrocidines A–D) containing ten amino 
acids [30]. Due to the toxicity of tyrothricin, it is used only as a topical antimicrobial 
agent, typically in combination with anesthetic agents (benzocaine, lidocaine, and 
others), anti-inflammatory drugs (hydrocortisone), or other antibiotics (neomycin). For 
example, it is found in throat lozenges or sprays used for the treatment of throat 
irritation and infection [31].  
 
Gramicidins were the first natural antibiotic discovered by means of a systematic, 
purposeful search for antibacterial compounds [1]. They are particularly effective 
against gram-positive bacteria and are mostly bacteriostatic, inhibiting bacterial growth, 
but at high concentrations they are also bactericidal. Gramicidin D is a heterogeneous 
mixture of three linear antibiotic pentadecapeptides: gramicidin A, B, and C. Like 
tyrothricin, they are produced by the soil bacterium Bacillus brevis. Gramicidin S is a 
cyclic decapeptide that is also active against a few gram-negative bacteria, such as those 
of the Neisseria genus. Gramicidins cannot be administered systemically because of 
their pronounced hemolytic side effects. Instead, they are mainly used to treat infected 
surface wounds as well as ocular, nasal, and throat infections. Gramicidin is also a 
component of an ophthalmic solution containing the  antibiotic neomycin and the AMP 
polymyxin B [32].  
 
The polymyxins were discovered in 1947 and entered into clinical use in the 1960s, 
including as systemic drugs. They consist of a mixture of cyclic lipodecapeptides, 
mainly polymyxin B and colistin (polymyxin E). They are highly active against gram-
negative bacteria, particularly most of the ESKAPE bacteria [33]. However, systemic 
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use was abandoned beginning in the late 1970s because of reports of their toxicity 
(mostly nephrotoxicity but also neuromuscular blockage and neurotoxicity) and the 
availability of new, safer therapeutic options. Thus, today, polymyxins are mostly used 
for topical applications, in the treatment of eye infections and for selective 
decontamination of the digestive tract. However, due to the scarcity of new antibiotics 
against multi-drug-resistant gram-negative bacteria,  polymyxins have been rescued as a 
last resort treatment in patients with serious infections for whom no other therapeutic 
options exist. In addition, recent clinical studies found that polymyxins have a better 
therapeutic window than originally reported and therefore that better dosing strategies 
with fewer secondary effects could be developed. One such strategy is the application of 
nanotechnologies to produce nanoparticulated polymixins [34,35]. In addition, a great 
deal of effort is currently being devoted to developing new polymyxin analogs with 
reduced toxicity [36–39]. 
 
Bacitracin is a cyclic peptide antibiotic commonly used in combination with polymyxin 
and neomycin (an aminoglycoside) as triple antibiotic ointment (Neosporin™) for the 
topical treatment of skin and eye infections. It is a complex mixture of related 
cyclopeptides produced by Bacillus subtilis var. Tracy. It was first isolated in 1945 from 
an infected wound that healed spontaneously in a pediatric patient with a complicated 
tibial fracture. Parenteral administration of bacitracin is highly restricted because it is 
nephrotoxic [32,40]. 
 
Daptomycin (Cubicin®) is also a cyclic lipodepsipeptide antibiotic that is anionic rather 
than cationic due to the presence of three aspartic acids and one methylglutamic acid not 
compensated by its single ornithine and kynurenine residues. It was approved by the 
FDA in 2003 for the treatment of complicated skin and skin-structure infections (cSSSI) 
caused by susceptible isolates of gram-positive bacteria, particularly S. aureus (also 
methicillin-resistant strains) and including bloodstream infections by this bacterium 
(bacteremia) such as in patients with right-sided infective endocarditis [41]. 
Among the promising analogs of daptomycin is surotomycin, (also known as CB-315, 
CB-183315, MK4261), obtained from the parent compound by semisynthetic 
modification of its lipid moiety. Surotomycin is effective in Clostridium difficile, 
disrupting the bacterial membrane, and is currently in phase III clinical trials for the 
treatment of C.-difficile-associated diarrhea. Due to its lack of activity against gram-
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negative anaerobes and facultative anaerobes, it minimally disturbs the normal 
gastrointestinal microbiota. In 2012, it was assigned Qualified Infectious Disease 
Product (QIDP) status in the USA, under the FDA’s GAIN Act, for the treatment of C.-
difficile-associated diarrhea. This means that priority review, fast-track status, and 5-
year exclusivity after licensing are applicable [42]. 
 
POL7080 (murepavadin) is a cyclic protegrin I analog highly active and selective 
against protein LptD of P. aeruginosa. It has novel mechanism of action, targeting, 
outer membrane biogenesis. In preclinical studies, POL7080 showed high antimicrobial 
activity against a broad panel of clinical isolates, including multi-drug 
resistant Pseudomonas strains. Excellent in vivo efficacy was reported in thigh, lung, 
and septicemia infection models [43]. Phase I clinical trial in healthy volunteers proved 
its clinical safety and tolerability, with no serious side effects. It is currently being 
tested in phase II clinical trials in patients suffering ventilator-associated bacterial 
pneumonia (VABP) or bronchiectasis [43,44]. In 2014, POL7080 received QIDP status 
for the treatment of VABP caused by P. aeruginosa. A recent phase I clinical trial 
(September 2016) has been approved to study the drug-drug interactions of POL7080 
and amikacin [45]. 
 
4.2 Linear AMPs  
In addition to cyclic analogs, several linear AMPs are at different stages of development 
(Fig. 2) [29,38,46]. 
 
Pexiganan, a 22-amino acid magainin analog, active against a broad spectrum of gram-
positive and gram-negative aerobic and anaerobic bacteria as well as fungi. In addition, 
it is active against several strains of resistant bacteria, including methicillin-resistant S. 
aureus (MRSA), vancomycin-resistant Enterococcus (VRE), producers of extended-
spectrum beta-lactamases (ESBL), and several multidrug resistant bacteria. Pivotal 
phase III clinical trials were initiated for pexiganan (Locilex, pexiganan cream 0.8%; 
Dipexium Pharmaceuticals) for the treatment of mild infections of diabetic foot ulcers. 
However, in October 2016, the manufacturer announced that top-line data from the 
OneStep Phase III trial of Locilex® did not meet establish the superiority of the drug 
(the primary clinical endpoint) versus vehicle plus standardized wound care. Thus, 
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Locilex is now being tested for use in skin and cSSI, such as infected surgical wounds, 
infected burns, and infected decubitus ulcers (pressure sores) [47].  
Omiganan (CLS001 or MBI-226), a cationic dodecapeptide derived from indolicin 
(isolated from bovine neutrophils), exhibits activity against gram-positive and gram-
negative bacteria as well as fungi. It is currently in phase II clinical trials for the 
treatment of acne vulgaris atopic dermatitis, genital warts, skin inflammation, and 
vulvar intraepithelial neoplasia. A phase III trial is underway testing omiganan for the 
topical treatment of the papules and pustules of rosacea, a chronic skin disease that 
affects over 14 million North. Americans and 45 million people globally [48]. 
 
SGX942 (dusquetide), also derived from indolicin, is a fully synthetic, 5-amino acid 
peptide that acts as an innate defense regulator. Its safety and tolerability have been 
demonstrated in healthy volunteers (phase I clinical trial). It was granted Fast Track 
status from the FDA for the treatment of oral mucositis caused by radiation and/or 
chemotherapy treatment in head and neck cancer patients [49]. A phase II clinical study 
of this application was completed at the end of 2016. Preclinical data indicated that 
SGX94 is active in models of a wide range of therapeutic indications, including the 
severe side effects of chemo- and/or radiation-therapy and inflammation. [50].  
LTX-109 (Lytixar) is a short cationic peptidomimetic developed for topical treatments. 
Its fast-acting bactericidal mode of action is due to the selective and ultra-rapid 
disruption of microbial membranes. It is in phase I/II trial for the treatment of treatment 
of mild diabetic foot infections and nasal decolonization of S. aureus, including MRSA. 
Another phase II clinical trial is examining its use in the treatment of uncomplicated, 
gram-positive, skin infection and impetigo [51]. 
The Karolinska Institut, Karolinska Development AB (Sweden) and its portfolio 
company, Promore Pharma (former Pergamum AB), are the owners of three clinical-
stage peptides (LL-37, PXL01 and DPK-060) developed for topical applications. These 
compounds are multifunctional, exhibiting broad antimicrobial activity but also 
modulating inflammation, immune functions, and wound-healing properties. They are 
thus intended for the treatment of chronic wounds, the prevention of scarring and 
adhesions, and, as antimicrobial agents. LL-37 (hCAP-18, derived from human 
cathelidicin) is being tested in a phase II clinical trial for the treatment venous leg 
ulcers. The results obtained thus far indicate a significantly improved healing rate 
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compared to placebo. Its enantiomer (D-LL-37) also shows broad-spectrum antibacterial 
activity, suggesting an unspecific mode of action of these compounds. A phase II 
clinical trial examining the use of PXL-01 in the prevention of post-surgical adhesions 
yielded a positive outcome and a phase III clinical trial has been started. A statistically 
significant improvement was also reported in a phase II clinical trial of DPK-060 in 
outer ear infections [52]. 
 
Brilacidin is an arylamide foldamer peptidomimetic small molecule synthetically 
derived from human defensins. It shows high antibiotic activity against both gram-
positive and gram-negative bacteria. A clinical phase IIb study comparing brilacidin to 
daptomycin for the treatment of acute bacterial skin and skin structure infections 
(ABSSSI) yielded excellent positive results. Brilacidin received QIDP designation in 
2012. In January 2016, Cellceutix announced a pivotal phase III trial of brilacidin for 
the treatment of ABSSSI infections caused by gram-positive bacteria [53]. 
 
The AMP C16G2 was designed to specifically target Streptococcus mutans, the acid-
producing bacterium associated with dental caries and tooth decay. The peptide contains 
two functional regions: an S.-mutans-selective targeting region and a broad-spectrum 
antimicrobial peptide (G2). Although it is bactericidal, via a membrane disruption 
mechanism similar to that of other AMPs, it does not affect other species in the oral 
biofilm. The target indication for C16G2 is the prevention of dental caries and related 
diseases of the oral cavity caused by microbial dysbiosis.. C16G2  (administered as a 
dental gel) successfully completed a phase II clinical trial as an anti-cavity drug [54,55].  
 
HB1345 (Helix Biomedix) is a synthetic lipohexapeptide with potent and broad 
spectrum antimicrobial activity when applied topically to skin infections. Its minimum 
inhibitory concentration (MIC) values against key pathogens, including 
Propionibacterium acnes, are in the 1–2 µg/ml range. HB1345 is in the preclinical 
phase for the treatment of acne, the lead indication chosen for this compound, based on 
its binding of lipoteichoic acid, involved in the inflammation that develops in acne. 
Similarly, HB1275 is a lipohexapeptide (no sequence disclosed) in the preclinical stage 
of development based on its potent antifungal activity against yeast and filamentous 
fungi, particularly Trichophyton (athlete’s foot, tinea capitis, and onychomycosis) [56]  
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Arenicin-3 is a 21-residue amphipathic β-hairpin peptide that contains two disulfide 
bridges. Isolated from the marine lugworm Arenicola marina, it binds to and disrupts 
the integrity of the outer and cytoplasmic membranes of gram-negative bacteria. The 
arenicin-3 analog AA139 is highly active against gram-negative ESKAPE pathogens, 
including multi-drug resistant strains, and is currently in pre-clinical development. 
Among the possible applications are the treatment of urinary tract infections caused by 
E. coli strains (currently being tested by Adenium Biotech) and of both hospital-
acquired and ventilation-associated pneumonia [57].  
4.3 Lantibiotics  
Lantibiotics are a naturally occurring class of AMPs that contain lanthionine, a non-
proteinogenic amino acid, These antimicrobials are produced by bacteria and include 
nisin, which is used as a food preservative (E324). However, lantibiotics are also in 
development to fight infections. The main difficulty their large-scale production, as 
standard fermentation methods typically result in only minute amounts. A few 
candidates are available, such as OG253 and OG716 (no structures disclosed). OG235, 
obtained from the Oragenics discovery platform, has shown efficacy   in an animal 
model of C. difficile enteritis (nonclinical testing). In 2015, it was at the FDA’s pre-
Investigational New Drug application stage. In August 2016, Oragenics announced 
positive results for OG716, a second-generation orally-active lantibiotic obtained from 
its Mutacin 1140 (MU1140) platform. Promising in vivo efficacy was reported, 
including decreased relapse and the reduced production of C. difficile spores compared 
to a vancomycin positive control[58]. 
The lantibiotic NVB333 is a semi-synthetic derivative of the lantibiotic 
deoxyactagardine that exerts its antimicrobial activity by inhibiting cell wall 
biosynthesis. NVB333 is under development for the systemic treatment of gram-
positive infections, including those caused by MRSA. It has also been proven to be 
active against strains resistant to currently available antibiotics, such as vancomycin, 
daptomycin, and linezolid. In vivo tests have shown high activity in murine models of 
thigh and lung infections and promising preliminary toxicology results [59]. 
  
5. SYNERGIMS AMONG AMPs 
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Due to their mechanism of action, in which the primary target is the bacterial 
membrane, AMPs are often effective against multiresistant bacteria. They are therefore 
excellent molecules to be combined with other antimicrobials to achieve more effective 
synergistic effects. For example, AMPs can be combined with antibiotics of low 
bacterial penetrability or when the mechanism of resistance involves the membrane. 
A study of the use of colistin in combination with an antibiotic allowed both a reduction 
of the effective dose of colistin and the increased activity of the combined 
antimicrobials. Moreover, synergies of colistin with different antibiotics have been 
described, including quinolones fosfomycin, and aminoglucosides [60]. 
Other unusual combinations of antimicrobials have been tested, some with promising 
results. For example, linezolid and glycopeptides  are antimicrobials used in to treat 
infections caused by gram-positive bacteria (gram-negatives are intrinsically resistant to 
these antimicrobials). Synergism between colistin and linezolid was demonstrated in 
vitro against A. baumannii clinical strains [61]. Colistin combined with glycopeptides 
was synergistic in vitro and in a Galleria mellonella model [62]. 
Among the most studied AMP synergies are colistin-carbapenem (β-lactams) [63,64] 
and, especially, AMPs with imipenem. The main mechanism of resistance to imipenem 
is a decrease in bacterial membrane permeability due to the lack of OprD, a porin used 
by imipenem to penetrate the outer membrane. The combination of imipenem with 
AMP could restore the ability of the former to penetrate the bacterial cell and thus 
bacterial susceptibility [37,65]. Rudilla et al. demonstrated the synergy between 
colistin-derived AMP38 and carbapenems in imipenem-resistant strains of  P. 
aeruginosa [37]. In general, synergy has been observed with many polymyxin 
analogues. Particularly good results have been obtained in their potentiation of the 
activity of large hydrophobic antibiotics, such as the macrolides azithromycin and 
erythromycin [26].  
The in vitro synergistic antibacterial activity of six proline-based cyclic dipeptides of 
natural origin [cyclo(D-Pro-L-Leu), cyclo(L-Pro-L-Met), cyclo(D-Pro-L-Phe), cyclo(L-
Pro-L-Phe), cyclo(L- Pro-L-Tyr), and cyclo(L-Pro-D-Tyr)] with β-lactamic antibiotics 
was reported by Kumar et al [66]. A synergistic effect of antibiotics with several newly 
developed short AMPs was described by Wang et al., who examined the combined 
activity of PMAP-36 and PRW4 with aminoglycosides [67].  
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The magainin analogue pexiganan MSI-78 is a 22-amino acid amphipathic peptide that 
showed synergy in combination with β-lactam antibiotics[68], suggesting its use against 
infections caused by P. aeruginosa, E. coli, S. aureus, and  S. epidermidis. 
The short AMP iseganan IB-367 (17-amino acid peptide) contains an amidated C-
terminus and two disulfide bridges (Cys5–Cys14 and Cys7–Cys12). Synergies between 
IB-367 and the cyclic AMP colistin in P. aeruginosa, E. coli, A. baumannii, and K. 
pneumoniae were demonstrated  in an in vitro checkerboard assay [69]. 
Nisin and its derivatives, nisin V (M21V) and nisin I4V, are lantibiotics with potent 
antibacterial activity against many gram-positive bacteria. Analysis by kill curves  
established that nisin V + penicillin or nisin I4V + chloramphenicol had enhanced 
inhibitory effects against S. aureus  and S. pseudintermedius, respectively, compared to 
the equivalent nisin A or when each antimicrobial was administered alone. These 
peptides have been used mainly in food microbiology [70] 
The synergy of AMPs with β-lactam inhibitors recommends the further investigation of 
these and other such combinations to enhance the activity of “classical” antimicrobial 
agents whose efficacy when used alone has been compromised by the emergence of 
resistant strains.  
6. AMPs and BIOFILMS  
Most pathogens have the ability to form stable biofilms, which are a common cause of 
both persistent and device-associated infections. Because bacteria in biofilms are much 
less sensitive to antimicrobial agents than planktonic microbes the treatment of biofilm-
type infections often fails. However, most AMPs are active against both planktonic and 
biofilm-forming bacteria, as demonstrated for KT2 and RT2, the semisynthetic peptide 
SB056, peptide 1018, and others. Other AMPs, such as LL-37, possess weak planktonic 
activity but show strong activity against biofilms [37,71]. Moreover, in addition to their 
ability to penetrate bacterial biofilms many AMPs prevent biofilm formation [18]. 
AMPs also enhance the activity of other antimicrobial agents when they are used in 
combination to treat infections involving biofilms. The broad-spectrum of activity 
shown by anti-biofilm AMPs includes interference with second messenger molecules 
and therefore signaling pathways, in both gram-positive and gram-negative bacteria 
[71]. 
Page 15 of 40
URL: http://mc.manuscriptcentral.com/eobt  Email: David.Grech@informa.com
































































~ 16 ~ 
 
However, several mechanisms of AMP resistance exhibited by biofilm bacteria have 
been described and threaten the effective use of these molecules. For instance, different 
bacterial subpopulations in the biofilm may differ in their motility or metabolism and 
thus be more resistant than others to AMPs. The development of resistance is also 
favored by the higher mutation rate of bacteria in biofilm communities than growing 
planktonically. The up-regulation of efflux pumps or operon genes in biofilms (e.g., the 
pmr operon of P. aeruginosa) can also lead to high levels of AMP resistance [72,73]. 
The ability of the biofilm itself to reduce the diffusion of large AMPs (periplasmic 
glucan in P. aeruginosa biofilms) has also been demonstrated, but whether the diffusion 
rates of all types of AMPs are affected remains to be determined [73].  
Despite these possible mechanisms of biofilm resistance, AMPs represent a novel and 
promising approach for the eradication of gram-positive and gram-negative bacteria in 
biofilms, which are mainly a feature of chronic and long-term infections. Additional 
work is needed to better understand the downstream processes of antibiofilm AMPs to 
allow the optimization of these drugs, when used either alone or in combination with 
other antimicrobial agents [71].  
 
7. ANTI-MYCOBACTERIAL PEPTIDES  
 
No novel drugs against Mycobacterium sp. have been introduced for clinical use in the 
past 40 years. AMPs offer a new approach and most of those investigated thus far for 
their efficacy against Mycobacterium spp. are either natural peptides or derived from 
natural peptides [74,75]. Several examples are provided in the following: 
Defensins such as HNP1-4 are human neutrophil peptides active on skin or other 
epithelial surfaces, usually in the presence of low concentrations of salt. HNPs kill 
mycobacteria probably by inhibiting the biosynthesis of macromolecules and/or 
increasing the permeability of the bacterial cell membrane [74]  
Lactoferrins are iron-binding proteins belonging to the transferrin family of proteins. 
Silva et al [76] studied the activity of human and bovine lactoferrins, including 
hLFcin1-11, LFcin17-30, and other  variants obtained by specific amino acid 
substitutions, reporting promising results with some of these peptides.  
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Cathelicidin or its terminal region (LL-37), an AMP already mentioned in this review, 
shows moderate activity against Mycobacterium tuberculosis H37Rv strains as well as 
Mycobacterium tuberculosis multidrug resistant strains, Its MIC is between 2 and 10 
µg/ml. Rivas-Santiago et al. also showed the activity of three LL37-related peptides: E2, 
E6, and CP26 [77]. 
Several synthetic peptides with antimycobacterial activity have been developed, 
including D-LAK peptides, which are linear, cationic, amphipathic α-helix-shaped 
AMPs [78] that at low concentrations have extracellular antimycobacterial activity; 
however, despite mild cytotoxicity against THP-1 cells they failed in completely 
eradicating intracellular mycobacteria. 
A library of small (~10 amino acids) synthetic AMPs, has been tested and some of the 
peptides exhibit interesting activities against M. tuberculosis and M. smegmatis . Their 
MIC values were as low as 1.1 µM and cytotoxicity against THP-1 cells was low [79] .  
8. ANTIFUNGAL PEPTIDES 
Echinocandins are antifungal peptides that show fungicidal activity against Candida spp 
and fungistatic activity against  Aspergillus spp. [80]. Many have been approved by the 
FDA and EMEA (European Medicine Agency) Caspofungin (Merck), Anidulafungin 
(Pfizer), and Micafungin (Astellas) have been available since the early 2000s and are 
widely used for the treatment of systemic candidemia and candidiasis. All of them are 
cyclic hexapeptides linked with a fatty acid chain (semisynthetic peptides) and were 
derived from pneumocandins (natural lipopeptides).  
NP213 is a cyclic arginine-based heptamer (Table 2) with fungicidal activity. As the 
active ingredient of Novexatin®, it has been formulated as a brush-on-treatment for 
fungal nail infections (onychomycosis). Phase I and IIa clinical studies demonstrated 
that NP213 is safe, well-tolerated, and effective. Novabiotics is also developing 
Novamycin (NP339), a novel antifungal peptide for the treatment of aspergillosis, 
candidiasis ,and cryptococcosis, as well as Novarifyn (NP432), an antibacterial peptide 
to treat infections by pathogens such as MRSA, P. aeruginosa, C. difficile, A. 
baumannii, and E. coli. Both are expected to undergo initial clinical studies in 2017 
[81]. 
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P113 (Table 2) is a 12-amino-acid cationic and amphipathic AMP derived from 
naturally occurring histatin 5, an oral defense protein found in saliva. Clinical phase I 
and II results showed that P113 is safe and effective in the treatment of gingivitis and 
oral candidiasis. In addition, non-prescription over-the-counter products containing 
P113, including a mouthwash, oral spray, and anti-bacterial hand cream, have recently 
become available [82] 
Qi et al. [83] described a series of short (9–11 amino acids) linear peptide with an α-
helical structure. Some (P11-5, P11-6, and P9-4) have shown promising activity against 
the yeast Candida albicans (MIC = 3.1 µg/ml) and against the filamentous fungi 
Fusarium solani (MICs = 12.5–50 µg/ml). Importantly, both of these antifungal 
peptides are of low toxicity. 
9. ANTI-PARASITIC PEPTIDES 
The diversity of parasitic groups, with their complex life cycles that typically involve 
multiple stages in different hosts and their  enormously different protein expression and 
membrane composition, have hindered the rapid development of AMPs for the 
treatment of parasitic disease [84]. 
Nevertheless, a broad range of AMPs (both naturally occurring peptides and their 
structural analogues) has been shown to be effective against a variety of parasitic 
infections caused by protozoa (Chagas disease, human African trypanosomiasis, 
malaria, and leishmaniosis), and helminths (taeniasis and onchocerciasis). Moreover, 
some of these microbes, for example the filarial worm Onchocerca volvulus, may be a 
source of novel AMPs with therapeutic potential against microbial infections [85]. 
A few examples of AMPs effective against parasitic diseases are provided in the 
following. 
9.1. Plasmodium 
Magainin-2 was one of the first anti-protozoal host defense peptide to be identified: Its 
anti-plasmodium activity was described over 35 years ago [86]. The inhibition of 
Plasmodium falciparum growth by the hybrid peptide cecropin-melittin (CA 1-13 and H 
1-13) has also been reported [87]. 
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Other anti-malarial peptides produced by insects are defensins (drosomycins), 
gambicins, and gomesin. Dermaseptins, of amphibian origin, are highly active against 
P. falciparum. A high level of antiplasmodial activity has been demonstrated for the 
acyl-derivative desmapeptin K4-S4 [88]. 
Scorpine, a peptide isolated from scorpion and spider’s venom, also has inhibitory 
activity against P. falciparum parasitemia, as do the synthetic antimalarial AMPs NK-2, 
D-HALO-rev, and IDR-1018. Some antimalarial peptides act selectively on infected 
erythrocytes, leaving the membranes of healthy cells undisturbed and are thus of 
particular interest as antimalarial drugs [89]. Their development is highly anticipated 
because artemisinin-resistance is becoming increasingly frequent, especially in Asia 
[90]. 
9.2. Trypanosoma brucei  
AMPs have a clear established role in the immunity of the African trypanosomiasis 
vector (tse-tse fly). For example, attacin, defensin, and cecropin participate in the 
insect’s innate immunity. Conversely, several trypanocidal peptides from mammalian 
hosts have also been described, including the α- and β defensins and cathelicidins ( 
sheep SMAP-29 and pig protegrin-1). All of then show in vitro trypanolytic activity 
against both procyclic and bloodstream forms of Trypanosoma brucei [91]. Peptide 
antibiotics isolated from fungi (leucinostatin A and B, alamethicin and tsushimycin) 
also exhibit trypanolytic activity both in vitro and in vivo, although in some cases with a 
high oral toxicity. 
Among the synthetic AMPs targeting T. brucei are the cell penetrating peptide 
transportan TP10, a derivate of bovine BMAP-27, and small synthetic peptides derived 
from insect defensins. In addition, unconventional AMPs, such as neuropetides, 
trypanosome lytic factor, and small hydrophobic peptides (SHP-1 and SHP-2), kill 
African trypanosomes mainly by increasing the rigidity of their membranes [92]. 
9.3. Trypanosoma cruzi 
Three classes of anti-trypanosomal peptides from insect sources have been extensively 
studied: apidecins, cecropins, and melittins. Cecropin and melittin, used as a hybrid in 
the treatment of malaria, have been combined with magainin 2 as an anti-trypanocidal 
agent with activity 10-fold higher than when used  alone. The synthetic cecropins SB-37 
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and Shiva-1 are 10 times more effective than natural cecropins in damaging and killing 
the parasite.  
Temporin peptides, the smallest amphipathic α-helical containing AMPs found in 
nature, are produced by frogs, which like other amphibians are naturally resistant to 
Trypanosoma cruzi infection. Temporin-SHd has significant inhibitory effect against 
trypanosomes but its toxicity to human cells has discouraged its use. Temporizin-1 is an 
artificial hybrid peptide containing pore-forming gramicidin but with a reduction in the 
region that inserts into membranes. Its moderate toxicity towards mammalian cells and 
improved anti-trypanosomal activity recommend its further development as a novel 
anti-trypanosomal drugs [93]. 
9.4. Leishmania 
Leishmanicidal peptides include temporins, bombins, magainins, and cathelicidins [94]. 
Dermaseptin S4 and its synthetic analogues potently induce the lysis of promastigotes. 
Anti- Leishmania activity has been demonstrated for the AMPs gomesin, indolicin, and 
thionins, isolated from different organisms. Pexiganan a synthetic magainin-based 
lysine-rich peptide, originally tested in a phase 3 clinical trial for diabetic foot ulcers but 
was also found to induce apoptosis in leishmanial promastigotes. 
Trichomonas and the intracellular parasites Criptosporidium parvum and C. hominis can 
also be killed by AMPs/HDPs.  
Peptide drugs for protozoan diseases are still in the early stages of testing, but the 
available evidence suggests that they will be effective in the treatment of malaria and 
other diseases. However, the continued development of AMPs for use in the treatment 
of Plasmodium or leishmanial infections depends on several factors, including a 
reduction of the high production costs, and an improvement of the stability of the drugs, 
and a reduction of the required dose, to avoid toxicity [95]. A promising strategy is the 
use of nanotechnologies and peptide encapsulation to increase the selectivity and half-
life of the drug.  
9.5. Taeniasis and cysticercosis 
Temporin A and iseganan IB-367 (a protegrin-1 derivative of the cathelicidins family) 
have antiparasitic effects against Taenia crassiceps, the causative agent of tapeworm. In 
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in vitro tests, both drugs damage the tegumentary surface of the cysticerci to induce 
morphological changes [96]. 
9.6. Onchocerca volvulus 
Extracts of O. volvulus obtained from infected patients were shown to also contain a 
human neutrophil peptide 1-3 (HNP 1-3), a defensin that mediates the macrophage 
response to microorganisms. HNP 1-3 binds to the surface of O. volvulus, which is not 
affected by the peptide. Others excretory/secretory products of Onchocerca were found 
to have significant antibacterial activity against Escherichia coli. 
Helminth defense molecules (HDMs) are a novel family of molecules secreted by 
helminthic parasites and exhibiting structural and biochemical characteristics similar to 
those of mammalian helminth defense peptides (HDPs) [97]. A comparison of four 
trematode cathelicidin-like HDMs derived from Schistosoma mansoni and Fasciola 
hepatica showed that unlike HDPs, they exhibit no antimicrobial activity and are non-
cytotoxic to mammalian cells (macrophages and red blood cells). However, both HDPs 
and HDMs suppress the activation of macrophages by microbial stimuli and alter the 
response of B cells to cytokine stimulation. These observations suggest that HDMs are a 
novel family of HDPs that evolved to regulate the immune responses of their 
mammalian hosts, by retaining potent immune modulatory properties without causing 
deleterious cytotoxic effects. This strategy allows helminths to modulate host immune 
responses in establishing an environment that facilitates the reproduction and survival of 
the parasite [98]. A phylogenetic analysis revealed that HDMs are conserved across the 
majority of trematode species, including liver flukes and blood flukes.  
In summary, HDMs hold promise as a more attractive therapeutic option than HDPs, as 
they show all the potent immunomodulatory effects of the latter without their cytotoxic 
and cytolytic effects. 
10. CONCLUSION 
Given the ubiquity of AMPs in nature and their production by almost all living 
organism, these peptides and their synthetic derivatives have become an interesting 
alternative to traditional antibiotics. This has been well-demonstrated by the renewed 
use of colistin as a first-line antimicrobial to treat severe infections caused by 
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multidrug-resistant microorganisms. Moreover, the AMP pipeline currently includes 
over 20 different compounds in all clinical stages of development. 
The importance of AMPs lies in their multiple mechanisms of action to produce a 
killing effect. This may prevent the development of bacterial resistance, which generally 
relies on more than a single mutational or adaptive event. Furthermore, the ability of 
AMPs to disrupt the bacterial membrane and thus alter its permeability makes them 
interesting compounds for use in synergistic combinations with other antimicrobial 
agents. 
11. EXPERT OPINION 
Antimicrobial peptides, also called host defense peptides (HDPs), were first discovered 
on the external surface of amphibians, in studies of why their nutritive and humid 
surface was not permanently infected, Since then these small molecules have been 
shown to form part of the innate immune response of almost (if not all) classes of life 
[99]. For instance, the polymorphonuclear neutrophils and natural killer cells of 
vertebrates produce AMPs active against microbes (including protozoa, fungi, and 
bacteria) and even tumor cells. Among bacteria, the genus Bacillus produces several 
AMPs of interest in human medicine, such as tyrothricin, gramicidin D, polymyxin B, 
and colistin. Indeed, the widely used antibiotic bacitracin is a mixture of bacterial 
AMPs. Among the other bacterial species that produce AMPs is Lactobacillus, whose 
peptides are extensively used in the food industry, including as L-antibiotics (nisin, 
lactacin, etc.) [70]. Also of interest are microcins, a family of plasmid-encoded AMPs 
secreted by Enterobacteria [100]. Fungal AMPs include the peptaibol family of 
peptides, which contain unusual amino acids. AMPs are also produced by plants and 
participate in plant defense (defensins) responses. Within the animal kingdom, AMP 
production is almost universal, with humoral defense peptides described in sponges, 
cnidarians, and mollusks. In these invertebrates living in marine and freshwater 
environments, AMPs are a fundamental strategy guaranteeing their survival. Among the 
AMPs prodced by arthropods are the positive charged cecropins, thanatin, melittin, 
apidaecins, and ceratotoxins. The defense strategies of fish also rely on AMPs [99], as 
demonstrated by cathelicidins and β-defensins, piscidins, and hepcidins, whose 
chemical structures and mechanisms of action are highly diverse. Amphibians produce 
many AMPs, including bombinins, cathelicidins, and dermaseptin, whose mechanisms 
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of action are highly diverse. Reptiles and birds, like other vertebrates, also produce 
AMPs belonging to the cathelicidin and defensin families. Besides AMPs belonging to 
the cathelicidin and defensin families, non-human mammals produce other well-
characterized AMPs, such as platelet antimicrobial proteins (PMPs), dermcidin, and 
hepcidins [99]. It remains unclear to what extent these AMPs play a central role in the 
highly evolved immune response of mammalians, although, in some cases, such as LL-
37 an amphipathic molecule that acquires an α-helical structure when interacting with 
cell membranes to form transmembrane pores, their role has been very well recognized.  
 
An appreciation of the diversity of AMPs in nature has stimulated the development of 
synthetic derivatives in the laboratory. They are gaining increasing importance given the 
dramatic rise in resistant bacteria [36], although both their antimicrobial action and 
cellular toxicity must be well-defined. Nonetheless, given the scarcity of new natural 
antimicrobials, synthetic AMPs are sure to be a promising path with which to improve 
the therapeutic arsenal against infectious diseases.  
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LEGENDS TO FIGURES 
 
FIGURE 1. Chemical structures and sequences of cyclic antimicrobial peptides 
commercially available or in development (POL7080), as described in the text. 
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FIGURE 2. Disclosed structures of linear antimicrobial peptides and peptidomimetics 
in development, as described in the text. Sequences are depicted in the single-letter 
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Table 1. Temporal relationship between the  antibiotic introduction in clinics and 
time of resistance development 
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Table 2: Selection, main properties and stage of development of pipeline AMPs. 
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 Article highlights 
• Antimicrobial peptides, potentially, offer advantages to become useful 
antimicrobials as they are less prone to generate microbial resistance. 
• There are circa of 20 new antimicrobial peptides  in diferent stages of 
development. 
• Natural antimicrobial peptides could be a starting point for the research on 
antimicrobial peptides. 
• Due to  the  main mechanism of action antimicrobial peptides could be a 
useful hope when used in combination with classical antibiotics. 
• Peptides with anti-mycobacterial, anti-fungal and anti-parasitic activities 
constitute also a promising family of compounds.  
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